The global viral vector and plasmid DNA manufacturing market accounted for $261 million in 2016, and is expected to reach $1090 million by 2023, registering a CAGR of 22.6% from 2017 to 2023. Viral vectors and plasmid DNA manufacturing commonly includes the use of system biology and panomics to determine the cause of a patient's illness at the molecular level, followed by the use of concentrated medications to address each patient's illness. Moreover, viral vectors and plasmid DNA can reduce the cost of treatment and help decrease repeated administration of medications. Research Beam Model: Research Beam Product ID: 2699406 5370 USD New
Viral Vector and Plasmid DNA Manufacturing Market by Product (Viral Vectors, Plasmid DNA, and Non-viral Vectors) and Application (Cancer, Inherited Disorders, Viral Infections, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Viral Vector and Plasmid DNA Manufacturing Market by Product (Viral Vectors, Plasmid DNA, and Non-viral Vectors) and Application (Cancer, Inherited Disorders, Viral Infections, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

 
  • Category : Diagnostic and Biotech
  • Published On : November  2017
  • Pages : 160
 
 

The manufacturing of viral vectors and plasmid DNA is based on a unique concept that states, two people infected with the same disease do not have same physical response toward the disease. However, it depends on the surrounding environment and influence of genes and symptoms of a patient. The global viral vectors and plasmid DNA manufacturing market was valued at $261 million in 2016, and is estimated to reach at $1,090 million by 2023, registering a CAGR of 22.6% from 2017 to 2023.

The global viral vectors and plasmid DNA manufacturing market is expected be driven by increase in global incidence of cancer and rise in aging population susceptible to disease. Moreover, government initiatives & grants and surge in investment by private companies on R&D related to viral vectors and plasmid DNA manufacturing are expected to boost the market growth.

The global viral vectors and plasmid DNA manufacturing market is segmented based on product, application, and geography. Based on product, it is divided into plasmid DNA, viral vectors, and non-viral vectors. Based on application, it is classified into cancer, inherited disorders, viral infections, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The report provides extensive competitive analysis and profiles of key market players such as Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene Therapy Catapult, FUJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, Cobra Biologics, UniQure and MassBiologics. Other players in the value chain analysis include, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd., and Thermo Fisher Scientific, Inc.

KEY MARKET BENEFITS

  • The study provides an in-depth analysis of the global viral vector and plasmid DNA manufacturing market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • The report presents quantitative analysis of the market from 2017 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on application assists in understanding the trends in the industry.
  • Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

By Product

  • Plasmid DNA
  • Viral Vectors
  • Non-viral Vectors

By Application

  • Cancer
  • Inherited Disorders
  • Viral Infections
  • Other

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.1.1. Increase in funding for R&D activities pertaining to gene therapy
3.4.1.2. Rise in prevalence of cancer, viral infection, and genetic disorders
3.4.1.3. Increase in awareness regarding gene therapy

3.4.2. Restraints

3.4.2.1. High cost associated with gene therapies
3.4.2.2. Risk of mutagenesis and other impediments in gene therapy

3.4.3. Opportunities

3.4.3.1. Increasing demand for synthetic genes
3.4.3.2. Untapped potential for emerging markets

CHAPTER 4 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. VIRAL VECTORS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. PLASMID DNA

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. NONVIRAL VECTORS

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. CANCERS

5.2.1. Market size and forecast

5.3. INHERITED DISORDERS

5.3.1. Market size and forecast

5.4. VIRAL INFECTIONS

5.4.1. Market size and forecast

5.5. OTHERS

5.5.1. Market size and forecast

CHAPTER 6 VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast, by product
6.2.3.2. U.S. market size and forecast, by application
6.2.3.3. Canada market size and forecast, by product
6.2.3.4. Canada market size and forecast, by application
6.2.3.5. Mexico market size and forecast, by product
6.2.3.6. Mexico market size and forecast, by application

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast, by product
6.3.3.2. Germany market size and forecast, by application
6.3.3.3. France market size and forecast, by product
6.3.3.4. France market size and forecast, by application
6.3.3.5. UK market size and forecast, by product
6.3.3.6. UK market size and forecast, by application
6.3.3.7. Italy market size and forecast, by product
6.3.3.8. Italy market size and forecast, by application
6.3.3.9. Spain market size and forecast, by product
6.3.3.10. Spain market size and forecast, by application
6.3.3.11. Rest of Europe market size and forecast, by product
6.3.3.12. Rest of Europe market size and forecast, by application

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. China market size and forecast, by product
6.4.3.2. China market size and forecast, by application
6.4.3.3. India market size and forecast, by product
6.4.3.4. India market size and forecast, by application
6.4.3.5. Japan market size and forecast product
6.4.3.6. Japan market size and forecast application
6.4.3.7. Australia market size and forecast product
6.4.3.8. Australia market size and forecast application
6.4.3.9. South Korea market size and forecast product
6.4.3.10. South Korea market size and forecast application
6.4.3.11. Taiwan market size and forecast product
6.4.3.12. Taiwan market size and forecast application
6.4.3.13. Rest of Asia-Pacific market size and forecast, by product
6.4.3.14. Rest of Asia-Pacific market size and forecast, by application

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast, by product
6.5.3.2. Brazil market size and forecast, by product
6.5.3.3. South Africa market size and forecast, by product
6.5.3.4. South Africa market size and forecast, by application
6.5.3.5. Saudi Arabia market size and forecast, by product
6.5.3.6. Saudi Arabia market size and forecast, by application
6.5.3.7. Rest of LAMEA market size and forecast, by product
6.5.3.8. Rest of LAMEA market size and forecast, by application

CHAPTER 7 COMPANY PROFILES

7.1. BRAMMER BIO, LLC

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Key strategic moves and developments

7.2. THE CELL THERAPY CATAPULT LIMITED

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Key strategic moves and developments

7.3. COBRA BIOLOGICS LTD

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Key strategic moves and developments

7.4. FINVECTOR VISION THERAPIES LIMITED

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio

7.5. FUJIFILM HOLDINGS CORPORATION (FUJIFILM DIOSYNTH BIOTECHNOLOGIES)

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. KANEKA CORPORATION (KANEKA EUROGENTEC S.A.)

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance

7.7. MASSBIOLOGICS

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio

7.8. SANOFI

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. SPARK THERAPEUTICS, INC.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance

7.10. UNIQURE N.V.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance

LIST OF TABLES

TABLE 1. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 2. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR VIRAL VECTORS, BY REGION, 2016-2023 ($MILLION)
TABLE 3. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR PLASMID DNA, BY REGION, 2016-2023 ($MILLION)
TABLE 4. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR NONVIRAL VECTORS, BY REGION, 2016-2023 ($MILLION)
TABLE 5. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023($MILLION)
TABLE 6. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR CANCERS, BY REGION, 2016-2023($MILLION)
TABLE 7. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR INHERITED DISORDERS, BY REGION, 2016-2023 ($MILLION)
TABLE 8. VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VIRAL INFECTIONS, BY REGION, 2016-2023($MILLION)
TABLE 9. VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHERS, BY REGION, 2016-2023($MILLION)
TABLE 11. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 12. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 13. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 14. U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 15. U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 16. CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 17. CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 18. MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 19. MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 20. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 21. E
TABLE 22. UROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 23. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 24. GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 25. GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 26. FRANCE. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 27. FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. UK. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 29. UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 30. ITALY. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 31. ITALY. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 32. SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 33. SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34. REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 35. REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 36. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 37. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 38. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 39. CHINA. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 40. CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 42. INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 43. JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 44. JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 45. AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 46. AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 47. SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 48. SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 49. TAIWAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 50. TAIWAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 51. REST OF ASIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 52. REST OF ASIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 53. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 54. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 55. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 56. BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 57. BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 58. SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 59. SOUTH AFRICA. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 60. SAUDI ARABIA. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 61. SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 62. REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 63. REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 64. BRAMMER BIO, LLC: COMPANY SNAPSHOT
TABLE 65. BRAMMER BIO, LLC: OPERATING SEGMENTS
TABLE 66. BRAMMER: PRODUCT PORTFOLIO
TABLE 67. THE CELL THERAPY CATAPULT LIMITED: COMPANY SNAPSHOT
TABLE 68. THE CELL THERAPY CATAPULT LIMITED: OPERATING SEGMENTS
TABLE 69. COBRA BIOLOGICS LTD.: COMPANY SNAPSHOT
TABLE 70. COBRA BIOLOGICS LTD: OPERATING SEGMENTS
TABLE 71. COBRA: PRODUCT PORTFOLIO
TABLE 72. FINVECTOR VISION THERAPIES LIMITED: COMPANY SNAPSHOT
TABLE 73. FINVECTOR VISION THERAPIES LIMITED: OPERATING SEGMENTS
TABLE 74. FINVECTOR: PRODUCT PORTFOLIO
TABLE 75. FUJIFILM: COMPANY SNAPSHOT
TABLE 76. FUJIFILM: OPERATING SEGMENTS
TABLE 77. FUJIFILM: PRODUCT PORTFOLIO
TABLE 78. KANEKA CORPORATION: COMPANY SNAPSHOT
TABLE 79. KANEKA CORPORATION: OPERATING SEGMENTS
TABLE 80. KANEKA EUROGENTEC S.A.: PRODUCT PORTFOLIO
TABLE 81. MASSBIOLOGICS: COMPANY SNAPSHOT
TABLE 82. MASSBIOLOGICS: OPERATING SEGMENTS
TABLE 83. MASSBIOLOGICS: PRODUCT PORTFOLIO
TABLE 84. SANOFI: COMPANY SNAPSHOT
TABLE 85. SANOFI: OPERATING SEGMENTS
TABLE 86. SANOFI: PRODUCT PORTFOLIO
TABLE 87. SPARK THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 88. SPARK THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 89. SPARK THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 90. UNIQURE N.V.: COMPANY SNAPSHOT
TABLE 91. UNIQURE N.V.: OPERATING SEGMENTS
TABLE 92. UNIQURE N.V.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS: GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET (2016)
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. FUJIFILM: NET SALES, 2014-2016 ($MILLION)
FIGURE 12. FUJIFILM: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 13. FUJIFILM: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 14. KANEKA CORPORATION: NET SALES, 2014-2016 ($MILLION)
FIGURE 15. KANEKA CORPORATION: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 16. KANEKA CORPORATION: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 17. SANOFI: NET SALE, 2014-2016 ($MILLION)
FIGURE 18. SANOFI: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 19. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 20. SPARK THERAPEUTICS, INC.: NET SALE, 2014-2016 ($MILLION)
FIGURE 21. UNIQURE N.V.: NET SALE, 2014-2016 ($MILLION)